CO5450246A1 - Vacuna - Google Patents
VacunaInfo
- Publication number
- CO5450246A1 CO5450246A1 CO00052321A CO00052321A CO5450246A1 CO 5450246 A1 CO5450246 A1 CO 5450246A1 CO 00052321 A CO00052321 A CO 00052321A CO 00052321 A CO00052321 A CO 00052321A CO 5450246 A1 CO5450246 A1 CO 5450246A1
- Authority
- CO
- Colombia
- Prior art keywords
- protein
- seq
- prostase
- vaccine
- fusion
- Prior art date
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Una proteína de fusión que incluye una proteína prostasa, fragmento u homologos de la misma, unida a un acompañante heterológo de fusión. Una proteína de acuerdo con la reivindicación 1, en la que el antígeno prostasa se selecciona del grupo formado por la SEQ ID N° 5, SEO ID N° 6, SEQ ID N° 7 y SEQ ID N° 8.1 Una vacuna de acuerdo con la reivindicación 10 u 11, en la que el adyuvante comprende 3D-MPL, QS21, un oligonucleótido CpG o un éter o éster de polietileno.1 Uso de una proteína o de un ácido nucleico de acuerdo con las presentes reivindicaciones, para la fabricación de una vacuna para tratar inmunoterapéuticamente un paciente que padece cáncer u otros tumores asociados con una prostasa.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/352,616 US6395278B1 (en) | 1997-02-25 | 1999-07-13 | Prostate specific fusion protein compositions |
| US09/439,313 US6329505B1 (en) | 1997-02-25 | 1999-11-12 | Compositions and methods for therapy and diagnosis of prostate cancer |
| US44368699A | 1999-11-18 | 1999-11-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5450246A1 true CO5450246A1 (es) | 2004-10-29 |
Family
ID=40913635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO00052321A CO5450246A1 (es) | 1999-07-13 | 2000-07-12 | Vacuna |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP2009142284A (es) |
| CO (1) | CO5450246A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7412344B2 (ja) * | 2018-10-04 | 2024-01-12 | 大塚製薬株式会社 | 補助情報の取得方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE302414T1 (de) * | 1997-02-25 | 2005-09-15 | Corixa Corp | Verbindungen zur immundiagnose von prostatakrebs und deren verwendung |
| NZ337446A (en) * | 1997-02-25 | 2001-02-23 | Corixa Corp | Immunogenic portions of a prostate protein and their use in immunotherapy of prostate cancer and methods for their use |
| WO1998050567A1 (en) * | 1997-05-02 | 1998-11-12 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the prostate |
| AU4823599A (en) * | 1998-06-22 | 2000-01-10 | Incyte Pharmaceuticals, Inc. | Prostate cancer-associated genes |
-
2000
- 2000-07-12 CO CO00052321A patent/CO5450246A1/es not_active Application Discontinuation
-
2009
- 2009-01-29 JP JP2009017430A patent/JP2009142284A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2009142284A (ja) | 2009-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9812472A (pt) | Vacina especìfica de mamaglobina, processo para tratar um paciente com um tumor que expressa mamaglobina, e, polipeptìdeo isolado e purificado | |
| Lingnau et al. | Poly-L-arginine synergizes with oligodeoxynucleotides containing CpG-motifs (CpG-ODN) for enhanced and prolonged immune responses and prevents the CpG-ODN-induced systemic release of pro-inflammatory cytokines | |
| PT1053325E (pt) | Derivados de antigenios associados a tumores da familia mage e, sequencias de acidos nucleicos que os codificam, utilizados para a preparacao de proteinas de fusao e de composicoes para vacinacao. | |
| CY1106103T1 (el) | Μεθοδος διαχωρισμου παραλλαγων ροταϊου και ζωντανο εξασθενημενο εμβολιο ροταϊου | |
| PE20050712A1 (es) | Anticuerpos rg1 | |
| ATE315090T1 (de) | Impfstoffherstellung des bacillus anthracis schutzantigens | |
| WO2002022686A3 (en) | Defensin-antigen fusion proteins | |
| PT1047446E (pt) | Composicao vacinica para o virus herpes simplex e metodos de utilizacao | |
| ATE219687T1 (de) | Verwendung von antikörpern zur vakzinierung gegen krebs | |
| AR036793A1 (es) | Vacunas de acido nucleico que utilizan acidos nucleicos que codifican un antigeno de tumor con un acido nucleico que codifica una citoquina como adyuvante | |
| CO5450246A1 (es) | Vacuna | |
| FR2746110B1 (fr) | Methode de traitement par therapie genique des tumeurs humaines et virus recombinants correspondants | |
| ES2181695T3 (es) | Vacuna recombinante contra la pleuroneumonia porcina. | |
| PT1272652E (pt) | Virus de herpes para a modulacao imunitaria | |
| UY26266A1 (es) | Antigeno asociado con tumores (r11) ley 17164 | |
| DE69720065D1 (de) | Therapeutische anwendungen von antigenen oder epitopen assoziert mit unvollständiger zellulärer peptidprozesierung , z.b.: exprimiert in rma-s zellen transfiziert mit b7-1 gen | |
| WO2002022687A3 (en) | Viral chemokine-tumur antigen fusion proteins | |
| ATE285250T1 (de) | Verwendung von polymeren der hyaluronsäure zur mukosalen freigabe von impfstoffen und adjuvantien | |
| UY27060A1 (es) | Composición vacunal que contiene factor de crecimiento transformante (tgf-alfa). su uso en la terapia de enfermedades malignas | |
| AR022662A1 (es) | Acidos nucleicos y proteinas del gen mhp3 de mycoplasma hyopneumoniae y sus usos | |
| CO5280140A1 (es) | Antigeno (c42) asociado a tumores | |
| AR023794A1 (es) | Antigeno asociado con tumores | |
| DK1151005T3 (da) | Peptidvarianter af tumormarkør MUC1 og deres anvendelse | |
| WO2001089281A3 (de) | Tumorassoziiertes antigen (b132), charakterisiert durch seq. id. no. 2 | |
| CY1113516T1 (el) | Νουκλεϊκο οξυ και αντιστοιχη πρωτεϊνη με ονομασια 158p1d7 χρησιμα στην αγωγη και ανιχνευση καρκινου ουροδοχου κυστης και αλλων καρκινων |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Application withdrawn |